Researchers reviewed the current hemophilia research that focuses on the development of improved longer-acting factor replacement therapies, particularly PEGylated products.
Articles by Margarida Azevedo, MSc
The European Medicines Agency (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) has initiated a review of factor VIII-containing medicines, to evaluate the…
A recent study involving adolescent and young adult patients with hemophilia, to evaluate racial and ethnic disparities in following recommended clotting…
A new study from Finland demonstrated that neutralizing antibodies (inhibitors)Â can develop in people with untreated hemophilia, and that early intensive…
San Rafael, California-based BioMarin Pharmaceutical will present interim data of an open-label, Phase 1/2 clinical trial of BMN 270, an investigational…
CSL Behring‘s new long-lasting recombinant factor VII single-chain therapy, Afstyla, for adults and children with hemophilia A, is now available…
Researchers investigated self-reported health-related quality of life (HrQoL) in children and adolescents with hereditary bleeding disorders, such as hemophilia A,…
Researchers from the PharmedOut project at Georgetown University Medical Center analyzed how pharmaceuticals market directly to people with hemophilia and found…
Researchers at the University of Tokyo reviewed the status of physical activity among hemophilia patients to discuss strategies to encourage…
uniQure N.V., a leading pharmaceutical specialized in human gene therapy, has presented additional data from its clinical trial in…